Ethical Considerations in Conducting Pediatric and Neonatal Research in Clinical Pharmacology

Michelle Roth-Cline1, Robert M Nelson

  • 1Pediatric Ethicist, Office of Pediatric Therapeutics, FDA, 10903 New Hampshire Ave, Bldg 32 Rm 5121 Silver Spring, MD 20993. Michelle.Roth-Cline@fda.hhs.gov.

Insights

Ensuring ethical pediatric clinical research is vital. This chapter outlines an ethical framework for pediatric drug and biological product studies, focusing on children's vulnerability and informed consent.

Area of Science:

  • Pediatric pharmacology
  • Bioethics
  • Clinical research ethics

Background:

  • Children require specific considerations in clinical research due to developmental and physiological differences.
  • Ethical oversight is paramount to protect children participating in studies involving drugs and biological products.
  • Existing ethical frameworks need adaptation for the unique context of pediatric research.

Purpose of the Study:

  • To review key ethical considerations for pediatric clinical research.
  • To present a foundational ethical framework to guide research involving children.
  • To explore the operationalization of this framework, linking scientific necessity with ethical principles.

Main Methods:

  • Literature review of ethical principles in human subjects research.
  • Analysis of ethical challenges specific to pediatric populations.
  • Discussion of the balance between research risks and potential benefits for children.
  • Examination of parental permission and child assent processes.

Main Results:

  • Children are recognized as a vulnerable population requiring enhanced protections.
  • A balanced approach to risk-benefit assessment is crucial in pediatric research design.
  • Parental permission and child assent are essential components of ethical research participation.
  • Operationalizing an ethical framework requires integrating scientific rigor with ethical safeguards.

Conclusions:

  • A robust ethical framework is necessary for scientifically sound and ethically responsible pediatric research.
  • Effective implementation involves careful consideration of children's vulnerability and consent processes.
  • Linking scientific objectives with ethical imperatives ensures the protection and well-being of pediatric participants.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
482
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
377
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
337
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
750
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
804
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.3K